Health link building (supplements, CBD and vape)

Health sits under the strictest quality standards Google applies. Medical results are dominated by institutions such as the NHS, Mayo Clinic, WebMD and Healthline. Supplements, CBD and vape are different: commercial, crowded and prone to spam. Prescription pharma has a criminal black market side built on hacked websites, which we describe in the high-risk markets playbook so that you can recognise it.

For a brand that wants to last, the link profile to aim for is the same across all of these: named medical reviewers, citations from health media, journals and universities, and nothing that looks like a claim.

What makes this market different

Authorship is part of the profile. The sites that win have medical reviewer bylines and are cited by journals, universities and health media. Supplement and CBD brands add lifestyle press, review sites, affiliates and podcasts.

Journalists are cautious. In BuzzStream’s 2026 State of Digital PR survey, health and wellness was the second hardest industry to earn coverage in, named by 20.3% of respondents. Only finance was harder.

Part of the sector is restricted. General health and wellness publishers are plentiful. CBD and cannabis are accepted by 35.4% of publishers in ESBO’s September 2026 dataset, so roughly two thirds of the pool is closed.

Advertising law comes first. In several product categories the question is whether a paid article is lawful at all, before any question about what Google thinks of the link.

What works

• Expert-led content cited by health journalists. A named clinician or researcher behind the content is what makes it citable.
• Original research and surveys. Data gives reporters something new. See digital PR.
• Medically reviewed tools. Calculators and checkers with a reviewer named on the page.
• Clinician quotes through journalist request platforms. A qualified expert answering a reporter’s question is one of the few scalable ways into health media.
• Product PR to lifestyle media. This suits supplements, where the product itself can be the story.
• Dispensary and local directories. For cannabis businesses where they are legal.
• Trade and advocacy press. Relevant, and more open to the niche than general media.
• Vape trade publications and review sites. A case study published by the agency Stan Ventures describes a monthly cadence of guest posts on vape, lifestyle and review sites for a vape client. It is a vendor’s own account, so read it as an example of the approach and not as proof of results.

What does not work

• Health claims in guest posts. A paid article that says a product helps a condition is a legal problem for the advertiser.
• Links from general “wellness” link farms. Sites that accept every supplement brand pass little and group you with the rest of their customers.
• Scholarship links. An old tactic with no relevance to a health brand.
• Anything implying treatment or cure. In copy, in anchors or in the page the link points to.

Prices and publisher acceptance

Benchmark	Figure	Source
Publishers accepting CBD and cannabis	35.4%	ESBO, September 2026
Median surcharge when priced separately	24%	Same dataset
Health and wellness guest post	$352 average	BuzzStream, 2026
Health and wellness link insertion	$136 average	BuzzStream, 2026
Global median sponsored article, all niches	$570	ESBO, September 2026
Agency placement in difficult niches	£800 to £1,000 or more	Solvid, agency rate

General health and wellness is one of the cheaper marketplace categories. That is a warning as much as a saving: BuzzStream’s 2026 analysis classed 96.2% of guest post sellers across all niches as low quality, and cheap wellness blogs are a large part of that pool. Check every site with the steps in how to vet a publisher.

For CBD, there is no clean 2026 price dataset. Practitioners commonly quote 1.5 to 3 times the general price, with many publishers refusing outright. That range is unverified. The one measured figure, ESBO’s 24% median surcharge at publisher level, suggests that much of any larger multiple is vendor margin and scarcity. The high-risk markets playbook explains why.

Regulation that touches links

Advertising rules differ by product and by country, and they apply to paid articles as well as to banner adverts.

• Prescription medicines. Advertising them to consumers is banned in the EU and most other countries, with the US and New Zealand the usual exceptions cited.
• Supplements. Health claims are regulated, through the EU health claims register and through FDA and FTC rules in the US. A claim that is not permitted on your packaging is not permitted in a sponsored article either.
• Vape and CBD. Rules on advertising and on the products themselves vary widely between countries and are changing. We have not verified the current position market by market, so we do not summarise it here. Check the law in each target country before paying for any placement.

This page is not legal advice.

Anchors and pace

Keep anchors brand-led and informational. Product-claim anchors are both a legal and an algorithmic risk. There is no published ratio to follow, so compare against the sites ranking for your terms, using the method in the anchor text guide.

On pace, the working norm is slow and steady. Health profiles are scrutinised, and a sudden run of bought placements on a young supplement site has no plausible cause. This is a rule of thumb from practitioners, not a measured threshold.

Which pages need the links

• Condition and ingredient guides
• The research hub
• Product category pages
• The lab results or certificates page
• Medical reviewer pages

Guides and research earn links most easily. Link from them to category pages internally. Reviewer pages and lab results deserve links too, because they support the trust signals of the whole site. See which pages need links.

Assets that fit this market: ingredient evidence databases, lab-test transparency reports, state and country legality maps, dosage calculators with medical review, and survey data. The build process is in linkable assets.

Common mistakes

• Anonymous authors. Health content without a named, qualified author or reviewer is weak before any link is built.
• Bad neighbourhoods. Buying links on sites that also sell to casino and adult brands.
• Ignoring advertising law in the target country. What is fine in one market can be unlawful in the next.
• Paying a large “CBD premium” without asking for the publisher’s direct price.

Where to go next

• Digital PR for the method behind most strong health profiles.
• Paid guest posts and niche edits for how paid placements work and what they risk.
• High-risk markets playbook for restricted-niche pricing and the brand asset test.
• Google link penalties and recovery if a previous campaign has left a problem.

We found no strong, named CBD link building case study, so none is cited here.